Initiated through Takeda’s Entrepreneurship Venture Program (EVP) initiative, SEEDSUPPLY will offer discovery screening services to global pharmaceutical companies and will be based in Takeda’s Shonan Research Center. Screening services will include state-of-the-art and unique binder selection technology. The EVP initiative was created to provide significant therapeutic options and healthcare solutions in areas outside of Takeda’s focus where the unmet medical need is high.

Takeda news release, August 1, 2017